ProBioGen signs commercial licence agreement with AstraZeneca for using GlymaxX technology EP News Bureau Feb 14, 2022 Following evaluation of the technology under a research license, AstraZeneca will now continue to use GlymaxX and will integrate…
ProBioGen licenses GlymaxX Technology to Bayer EP News Bureau Sep 11, 2019 Bayer will leverage the technology to further increase the potency of an undisclosed antibody candidate for oncological…
